

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



SSX1 shRNA (h) Lentiviral Particles: sc-44120-V



The Power to Question

BACKGROUND

The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1-5, are transcriptional repressors that contain a repressor domain in their carboxy termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SSX1 (synovial sarcoma, X breakpoint 1), also known as SSRC or CT5.1 (cancer/testis antigen 5.1), is a 188 amino acid protein that is implicated in transcription modulation and belongs to the SSX family. Highly expressed in testis, SSX1 is also found in rhabdomyosarcoma and fibrosarcoma cell lines, but is expressed only at low levels in thyroid.

REFERENCES

- Clark, J., et al. 1994. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 7: 502-508.
- Crew, A.J., et al. 1995. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Krüppel-associated box in human synovial sarcoma. EMBO J. 14: 2333-2340.
- Chand, A., et al. 1995. Long-range organization of reiterated sequences, including the SSX1 cDNA at the OATL1 cluster in Xp11.23. Genomics 30: 545-552.
- de Leeuw, B., et al. 1995. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum. Mol. Genet. 4: 1097-1099.
- Kawai, A., et al. 1998. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med. 338: 153-160.

CHROMOSOMAL LOCATION

Genetic locus: SSX1 (human) mapping to Xp11.23.

PRODUCT

SSX1 shRNA (h) Lentiviral Particles is a pool of concentrated, transduction-ready viral particles containing 2 target-specific constructs that encode 19-25 nt (plus hairpin) shRNA designed to knock down gene expression. Each vial contains 200 µl frozen stock containing 1.0 x 10⁶ infectious units of virus (IFU) in Dulbecco's Modified Eagle's Medium with 25 mM HEPES pH 7.3. Suitable for 10-20 transductions. Also see SSX1 siRNA (h): sc-44120 and SSX1 shRNA Plasmid (h): sc-44120-SH as alternate gene silencing products.

STORAGE

Store lentiviral particles at -80° C. Stable for at least one year from the date of shipment. Once thawed, particles can be stored at 4° C for up to one week. Avoid repeated freeze thaw cycles.

APPLICATIONS

SSX1 shRNA (h) Lentiviral Particles is recommended for the inhibition of SSX1 expression in human cells.

SUPPORT REAGENTS

Control shRNA Lentiviral Particles: sc-108080. Available as 200 μ l frozen viral stock containing 1.0 x 10 6 infectious units of virus (IFU); contains an shRNA construct encoding a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SSX1 gene expression knockdown using RT-PCR Primer: SSX1 (h)-PR: sc-44120-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

BIOSAFETY

Lentiviral particles can be employed in standard Biosafety Level 2 tissue culture facilities (and should be treated with the same level of caution as with any other potentially infectious reagent). Lentiviral particles are replication-incompetent and are designed to self-inactivate after transduction and integration of shRNA constructs into genomic DNA of target cells.

RESEARCH USE

The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and all replicates and derivatives for research purposes conducted by the buyer in his laboratory only (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party, or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com